RTRan Taube

Ran Taube

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ran Taube has a total of 111 co-authors. Here are the top co-authors by number of shared publications:

  • Alona Kuzmina

    The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel

    17 shared publications
  • Alona Kuzmina

    The Shraga Segal Department of Microbiology Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel

    5 shared publications
  • Elli Rosenberg

    Soroka Medical Center, Beer Sheva, Israel

    5 shared publications
  • Aner Ottolenghi

    The Shraga Segal Department of Microbiology Immunology and Genetics Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel

    4 shared publications
  • Ayelet Keren-Naus

    Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

    4 shared publications
  • Olga Voloshin

    Laboratory of Virology, Soroka University Medical Center, Beer-Sheva, Israel

    4 shared publications

Latest Publications

  • Open Access

    Inhibition of CDK12/CDK13-CYCLIN K rewires P-TEFb signaling to reverse HIV-1 latency and modulate cellular gene expression

    by Praveenkumar Murugavelu, Jagrity Rani, Heli Glebko, Ina Ambiel, Nadine Tibroni, Nili Tickotsky, Ferdinand Heyn, Philipp Schommers, Liron Levin, Alona Kuzmina, et al.

    Persistent HIV-1 latency in long-lived CD4⁺ T-cell reservoirs remains a major obstacle towards viral eradication. Current antiretroviral therapy (cART) exhibits limited clinical efficacy, highlighting the need for new therapeutic interventions. Here, we identify the CDK12/CDK13-Cyclin K (CCNK) complex as a regulator of HIV-1 latency. Pharmacological inhibition of CDK12/CDK13-CCNK with the SR-4835 inhibitor robustly reversed HIV-1 latency in the absence of additional stimuli, both in T cell models and in primary CD4⁺ T cells from people living with HIV-1 receiving cART. Targeting of CDK12/CDK13-CCNK with SR-4835 further synergized HIV-1 latency reversal and enhanced viral reactivation when co-treated with established Latency Reversal Agents. Mechanistically, CDK12/CDK13-CCNK inhibition promoted the release of P-TEFb (CDK9/CYCLIN T) from its inhibitory 7SK snRNP complex, resulting in increased recruitment of RNA polymerase II, CDK9 activation, and remodeled chromatin that overall drove productive HIV-1 transcription. Beyond HIV-1 reactivation, our findings reveal a previously unrecognized compensatory interplay between transcriptional kinases that activate gene expression, thereby rewiring cellular transcriptional programs. Together, this study identifies CDK12/CDK13-CCNK complex as a therapeutic target for HIV-1 latency reversal and provides a mechanistic rationale for improving strategies aimed at achieving an HIV cure.

  • Open Access

    Targeting CDK12/CYCLIN K induces HIV gene activation and latency reversal which is mediated by P-TEFb

    by Praveenkumar Murugavelu, Heli Glebko, Jagrity Rani, Nili Tickotsky, Liron Levin, Alona Kuzmina, Ran Taube

    The administration of antiretroviral therapy has successfully suppressed the replication of Human immunodeficiency virus and substantially inhibited viral infection. However, HIV still persists in long-lived infected cell reservoirs that are resistant to therapy and to immune clearance, therefore a barrier for elimination of infection. HIV gene expression is tightly regulated by the cellular transcription machinery, where low levels of host and viral transcription factors and epigenetic constrains maintain viral persistence. Here, we show that selective targeting of CDK12/CYCLIN K (CCNK) induces both HIV-specific and a global gene activation program, which is mediated by positive transcription elongation factor b (P-TEFb). Targeting CDK12/CCNK triggers a robust HIV gene expression, accompanied with latency reversal and synergistic reactivation when combined with latency-reversing agents. Mechanistically, CDK12/CCNK inhibition promotes the recruitment of RNA Polymerase II and CDK9 to the viral promoter, accompanied with elevated levels of histone activation makers. Targeting CDK12/ CCNK also exerts a global gene activation program, by releasing P-TEFb from 7SK snRNP, and reshaping the chromatin landscape at promoter-proximal loci and gene bodies. Together, these results uncover a previously unrecognized compensatory interplay between transcriptional kinases that rewires the cellular gene expression program with implications for HIV latency reversal. IMPORTANT: Manuscripts submitted to Review Commons are peer reviewed in a journal-agnostic way. Upon transfer of the peer reviewed preprint to a journal, the referee reports will be available in full to the handling editor. The identity of the referees will NOT be communicated to the authors unless the reviewers choose to sign their report. The identity of the referee will be confidentially disclosed to any affiliate journals to which the manuscript is transferred. GUIDELINES: For reviewers: https://www.reviewcommons.org/reviewers For authors: https://www.reviewcommons.org/authors CONTACT: The Review Commons of f ice can be contacted directly at: office@reviewcommons.org

  • Open Access

    Genome-wide CRISPR knockout screen identifies activating transcription factor (ATF1) as an activator of HIV gene expression

    by Alona Kuzmina, Seraj Wattad, Praveenkumar Murugavelu, Noa Amir, Nili Tickotsky, Liron Levin, Ran Taube

    Antiretroviral therapy against the human immunodeficiency virus (HIV) has significantly prolonged the life span of people living with HIV, transforming viral infection into a latent condition that is characterized with undetectable viral loads. Yet, a complete cure of infection is out of reach, as transcriptionally silent but replication-competent proviruses persist in a long-lived reservoir that is resistant to therapy. The current work follows a genome-wide CRISPR knockout screen in human CD4 + T cells and defines the activating transcription factor 1 (ATF1) as an activator of HIV gene transcription with elevated expression levels in cells that carry transcriptionally active provirus. Additional gain and loss-of-function experiments show that depletion of ATF1 promotes latency. ATF1 directly occupies the HIV promoter, where it regulates the recruitment of RNA Polymerase II and the levels of H3K9me3 histone repression mark. Genome-wide, ATF1 binds cellular gene promoters. Among its targets, ATF1 modulates the levels of CCR5 antisense lncRNA, thereby regulating the protein expression of the CCR5 HIV co-receptor. We conclude that ATF1 is an activator of gene transcription that dictates HIV gene expression via both direct and indirect mechanisms. IMPORTANCE: HIV persists in resting CD4 + primary infected cells, forming a reservoir that is resistant to therapy, and thus a main barrier toward elimination of viral infection. An understanding of the mechanisms that control HIV gene expression and drive viral latency is therefore of high clinical importance. This study identifies activating transcription factor 1 (ATF1) as an activator of HIV gene expression. ATF1 binds the HIV promoter, where it modulates the occupancy of RNA Polymerase II and the levels of H3K9me3 histone repression mark. Genome-wide, ATF1 also occupies cellular promoters. One target of ATF1 is the antisense (AS) lncRNA. Through binding to CCR5-AS lncRNA, ATF1 induces CCR5 mRNA stability, thereby indirectly controlling HIV infection. Overall, we provide an additional understanding of the host transcription pathways that regulate HIV gene expression and potentially open new ways to manipulate its reservoir size.

  • Open Access

    Engineering non-pathogenic bacteria for auto-transporter-driven secretion of functional interferon

    by May Tfilin Samuel, Irina Rostovsky, Alona Kuzmina, Ran Taube, Neta Sal-Man

    In recent years, various strategies have been developed to enable the oral administration of protein-based drugs (biologics) with the aim of overcoming the degradation and inactivation of these drugs that can occur as they traverse the gastrointestinal tract (GIT). In this study, we investigated bacteria as a delivery vehicle for biologics, harnessing their ability to withstand the harsh gastric environment and deliver therapeutic drugs directly to the intestine. Specifically, we explored using the type 5 secretion system (T5SS) to secrete therapeutic cargoes under simulated gut conditions. Our research focused on EspC, a T5SS protein from enteropathogenic Escherichia coli, and its potential to secrete interferon-α (IFNα), a cytokine with immunomodulatory and antiviral properties widely used in the clinic. We demonstrated that EspC can facilitate the secretion of IFNα variant when expressed in nonpathogenic bacteria. Moreover, this EspC-secreted IFN was able to activate the JAK-STAT pathway, upregulate IFN-stimulated genes, and induce a robust antiviral response in cells. Collectively, these findings provide proof of concept supporting the utilization of the EspC protein as a novel delivery platform for protein-based therapeutics.


  • Open Access

    Direct and indirect effects of CYTOR lncRNA regulate HIV gene expression

    by Alona Kuzmina, Lopamudra Sadhu, Hasanuzzaman, Koh Fujinaga, Jacob C. Schwartz, Oliver T. Fackler, Ran Taube

    The implementation of antiretroviral therapy (ART) has effectively restricted the transmission of Human Immunodeficiency Virus (HIV) and improved overall clinical outcomes. However, a complete cure for HIV remains out of reach, as the virus persists in a stable pool of infected cell reservoir that is resistant to therapy and thus a main barrier towards complete elimination of viral infection. While the mechanisms by which host proteins govern viral gene expression and latency are well-studied, the emerging regulatory functions of non-coding RNAs (ncRNA) in the context of T cell activation, HIV gene expression and viral latency have not yet been thoroughly explored. Here, we report the identification of the Cytoskeleton Regulator (CYTOR) long non-coding RNA (lncRNA) as an activator of HIV gene expression that is upregulated following T cell stimulation. Functional studies show that CYTOR suppresses viral latency by directly binding to the HIV promoter and associating with the cellular positive transcription elongation factor (P-TEFb) to activate viral gene expression. CYTOR also plays a global role in regulating cellular gene expression, including those involved in controlling actin dynamics. Depletion of CYTOR expression reduces cytoplasmic actin polymerization in response to T cell activation. In addition, treating HIV-infected cells with pharmacological inhibitors of actin polymerization reduces HIV gene expression. We conclude that both direct and indirect effects of CYTOR regulate HIV gene expression.


  • Open Access

    Role of long noncoding RNA in regulating HIV infection—a comprehensive review

    by Noa Amir, Ran Taube

    A complete cure against human immunodeficiency virus (HIV) infection remains out of reach, as the virus persists in stable cell reservoirs that are resistant to antiretroviral therapy. The key to eliminating these reservoirs lies in deciphering the processes that govern viral gene expression and latency. However, while we comprehensively understand how host proteins influence HIV gene expression and viral latency, the emerging role of long noncoding RNAs (lncRNAs) in the context of T cell activation, HIV gene expression, and viral latency remain unexplored. This review dives into the evolving significance of lncRNAs and their impact on HIV gene expression and viral latency. We provide an overview of the current knowledge regarding how lncRNAs regulate HIV gene expression, categorizing them as either activators or inhibitors of viral gene expression and infectivity. Furthermore, we offer insights into the potential therapeutic applications of lncRNAs in combatting HIV. A deeper understanding of how lncRNAs modulate HIV gene transcription holds promise for developing novel RNA-based therapies to complement existing treatment strategies to eradicate HIV reservoirs.


  • Open Access

    Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2

    by Tomer Hertz, Shlomia Levy, Daniel Ostrovsky, Hanna Oppenheimer, Shosh Zismanov, Alona Kuzmina, Lilach M. Friedman, Sanja Trifkovic, David Brice, Lin Chun-Yang, et al.

    Vaccination, especially with multiple doses, provides substantial population-level protection against COVID-19, but emerging variants of concern (VOC) and waning immunity represent significant risks at the individual level. Here we identify correlates of protection (COP) in a multicenter prospective study following 607 healthy individuals who received three doses of the Pfizer-BNT162b2 vaccine approximately six months prior to enrollment. We compared 242 individuals who received a fourth dose to 365 who did not. Within 90 days of enrollment, 239 individuals contracted COVID-19, 45% of the 3-dose group and 30% of the four-dose group. The fourth dose elicited a significant rise in antibody binding and neutralizing titers against multiple VOCs reducing the risk of symptomatic infection by 37% [95%CI, 15%-54%]. However, a group of individuals, characterized by low baseline titers of binding antibodies, remained susceptible to infection despite significantly increased neutralizing antibody titers upon boosting. A combination of reduced IgG levels to RBD mutants and reduced VOC-recognizing IgA antibodies represented the strongest COP in both the 3-dose group (HR = 6.34, p = 0.008) and four-dose group (HR = 8.14, p = 0.018). We validated our findings in an independent second cohort. In summary combination IgA and IgG baseline binding antibody levels may identify individuals most at risk from future infections.


  • Open Access

    Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity

    by Alona Kuzmina, Dina Korovin, Ido Cohen Lass, Nofar Atari, Aner Ottolenghi, Pan Hu, Michal Mandelboim, Benyamin Rosental, Elli Rosenberg, Felipe Diaz-Griffero, et al.


  • Open Access

    Correlates of protection for booster doses of the BNT162b2 vaccine

    by Tomer Hertz, Shlomia Levy, Daniel Ostrovsky, Hannah Oppenheimer, Shosh Zismanov, Alona Kuzmina, Lilach M Friedman, Sanja Trifkovic, David Brice, Lin Chun-Yang, et al.

    Introduction Variants of concern (VOC) of SARS-CoV2 and waning immunity pose a serious global problem. Herein, we aimed to identify novel correlates of protection (COPs) against symptomatic SARS-CoV-2 infection. Methods We conducted a Multicenter prospective study assessing the association between serological profiles and the risk for SARS-CoV-2 infection, comparing those vaccinated with three to four doses of Pfizer BNT162b2 vaccine. Results Of 608 healthy adults, 365 received three doses and 243 received four doses. During the first 90 days of followup, 239 (39%) were infected, of whom 165/365 (45%) received 3 doses and 74/243 (30%) four doses. We found that the fourth dose elicited a significant rise in antibody binding and neutralizing titers against multiple variants, and reduced the risk of symptomatic infection by 37% [95% I, 15% - 54%]. We found several binding IgG and IgA markers and their combinations that were COPs. The strongest association with infection risk was IgG levels to RBD mutants and IgA levels to VOCs, which was a COP in the three-dose group (HR=6.34, p=0.008) and in the four-dose group (HR=8.14, p=0.018). A combination of two commercially available ELISA assays were also associated with protection in both groups (HR = 1.84, p = 0.002; HR = 2.01, p = 0.025, respectively). In a subset, comparing those with low to high antibody levels before 4th dose, despite a significant rise in neutralizing antibody titers against both omicron variants, the number of infections in the low group (n=16) was significantly higher than in the high group (n=7, 43% vs. 20%, p=0.051). Conclusions We demonstrated that following immunization with three or four vaccine doses, combinations of IgA and IgG levels are associated with protection from symptomatic infection. In addition, we identified a subpopulation of healthy adult individuals with low-baseline levels of antibodies after 3 doses which are at an increased risk for SARS-CoV-2 infection despite receiving a fourth dose. These findings warrant further study of this group, assessing whether they are at a higher risk for developing severe disease or may spread infection more readily than others.


  • Open Access

    P681 mutations within the polybasic motif of spike dictate fusogenicity and syncytia formation of SARS CoV-2 variants

    by Alona Kuzmina, Nofar Atari, Aner Ottolenghi, Dina Korovin, Ido Cohen Lass, Benyamin Rosental, Elli Rosenberg, Michal Mandelboim, Ran Taube

    The rapid spread and dominance of the Omicron SARS-CoV-2 over its Delta variant has posed severe global challenges. While extensive research on the role of the Receptor Binding Domain on viral infectivity and vaccine sensitivity has been documented, the role of the spike 681 PRRAR/SV 687 polybasic motif is less clear. Here we monitored infectivity and vaccine sensitivity of Omicron SARS-CoV-2 pseudovirus against sera samples that were drawn four months post administration of the third dose of BNT162b2 mRNA vaccine. Our findings show that relative to Wuhan-Hu and Delta SARS-CoV-2, Omicron displayed enhanced infectivity and a sharp decline in its sensitivity to vaccine-induced neutralizing antibodies. Furthermore, while the spike proteins form Wuhan-Hu (P681), Omicron (H681) and BA.2 (H681) pseudoviruses modestly promoted cell fusion and syncytia formation, Delta spike (P681R) displayed enhanced fusogenic activity and syncytia formation capability. Live-viruses plaque formation assays confirmed these findings and demonstrated that relatively to the Wuhan-Hu and Omicron SARS-CoV-2, Delta formed more plaques that were smaller in size. Introducing a single P681R point mutation within the Wuhan-Hu spike, or H681R within Omicron spike, restored fusion potential to similar levels observed for Delta spike. Conversely, a R681P point mutation within Delta spike efficiency abolished fusion potential. We conclude that over time, the efficiency of the third dose of the Pfizer vaccine against SARS CoV-2 is waned, and cannot neutralize Omicron. We further verify that the P681 position of the viral spike dictates fusogenicity and syncytia formation.